Felipe Auba-Villacampa

Pamplona, NC 31008, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Adjuvant therapy in renal cell carcinoma. Does the end justify the means? A reflection on KEYNOTE-564 and LITESPARK-022 benefits and harms.

Adjuvant therapy in renal cell carcinoma. Does the end justify the means? A reflection on KEYNOTE-564 and LITESPARK-022 benefits and harms.

Journal: The Journal of urology

Published: August 28, 2026

Enhanced Endoscopic Imaging Technologies in Upper Urinary Tract Urothelial Tumors: Implications for Kidney-Sparing Surgery-A Narrative Review.

Enhanced Endoscopic Imaging Technologies in Upper Urinary Tract Urothelial Tumors: Implications for Kidney-Sparing Surgery-A Narrative Review.

Journal: Diagnostics (Basel, Switzerland)

Published: May 13, 2026

BAP1 and PBRM1 Loss Is Associated with Aggressive Clinicopathological Features in Clear Cell Renal Cell Carcinoma: Prognostic Implications in a 10-Year Surgical Cohort.

BAP1 and PBRM1 Loss Is Associated with Aggressive Clinicopathological Features in Clear Cell Renal Cell Carcinoma: Prognostic Implications in a 10-Year Surgical Cohort.

Journal: Diagnostics (Basel, Switzerland)

Published: April 01, 2026

Latest developments in urinary tumor DNA and its current clinical role in urothelial bladder cancer and upper tract urothelial carcinoma.

Latest developments in urinary tumor DNA and its current clinical role in urothelial bladder cancer and upper tract urothelial carcinoma.

Journal: Current opinion in urology

Published: March 13, 2026

Diagnostic Role and Clinical Impact of Zr-Girentuximab PET-CT for the Diagnosis and Treatment of Clear-Cell Renal Cell Carcinoma.

Diagnostic Role and Clinical Impact of Zr-Girentuximab PET-CT for the Diagnosis and Treatment of Clear-Cell Renal Cell Carcinoma.

Journal: Diagnostics (Basel, Switzerland)

Published: January 31, 2026

Immune Checkpoint Inhibitors for High-Risk Nonmuscle-Invasive Bladder Cancer: Lessons Learned From the CREST and POTOMAC Trials.

Immune Checkpoint Inhibitors for High-Risk Nonmuscle-Invasive Bladder Cancer: Lessons Learned From the CREST and POTOMAC Trials.

Journal: The Journal of urology

Published: November 25, 2025

Impact of Intravesical BCG Therapy on Quality of Life in Non-Muscle-Invasive Bladder Cancer: A Prospective Evaluation Using The FACT-Bl Questionnaire.

Impact of Intravesical BCG Therapy on Quality of Life in Non-Muscle-Invasive Bladder Cancer: A Prospective Evaluation Using The FACT-Bl Questionnaire.

Journal: Actas urologicas espanolas

Published: November 19, 2025

Efficacy of Oral Mucosal Grafting for Nasal, Septal, and Sinonasal Reconstruction: A Systematic Review of the Literature.

Efficacy of Oral Mucosal Grafting for Nasal, Septal, and Sinonasal Reconstruction: A Systematic Review of the Literature.

Journal: Life (Basel, Switzerland)

Published: June 29, 2025

Initial clinical experience with Zr-Girentuximab PET-CT for the evaluation of renal masses in patients with solitary kidneys.

Initial clinical experience with Zr-Girentuximab PET-CT for the evaluation of renal masses in patients with solitary kidneys.

Journal: Actas urologicas espanolas

Published: December 11, 2024

Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

Journal: Translational andrology and urology

Published: November 08, 2023

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: December 09, 2022

Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.

Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.

Journal: The Journal of urology

Published: September 08, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026